Eloxx Pharmaceuticals, Inc. financial data

Symbol
ELOX on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
480 Arsenal Way, Suite 130, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Sevion Therapeutics, Inc. (to 12/22/2017), SENESCO TECHNOLOGIES INC (to 9/29/2014), NAVA LEISURE USA INC (to 5/24/1999)
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 43 % -78.8%
Debt-to-equity -321 % -184%
Return On Equity 248 %
Return On Assets -203 % -80.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.14M shares -96.4%
Common Stock, Shares, Outstanding 2.17M shares -97.5%
Entity Public Float 16.7M USD -87.9%
Common Stock, Value, Issued 31K USD -96.4%
Weighted Average Number of Shares Outstanding, Basic 2.75M shares +26.8%
Weighted Average Number of Shares Outstanding, Diluted 2.75M shares +26.8%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 8.92M USD -23.7%
Operating Income (Loss) -19.3M USD +51.8%
Net Income (Loss) Attributable to Parent -20.5M USD +51%
Earnings Per Share, Basic -9.07 USD/shares +62.2%
Earnings Per Share, Diluted -9.07 USD/shares +62.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.78M USD -80.6%
Assets, Current 5.63M USD -78.1%
Property, Plant and Equipment, Net 107K USD -50.2%
Operating Lease, Right-of-Use Asset 306K USD -69.2%
Assets 6.04M USD -77.5%
Accounts Payable, Current 3.13M USD +96.5%
Employee-related Liabilities, Current 122K USD -74.8%
Accrued Liabilities, Current 2.44M USD -46%
Liabilities, Current 23.5M USD +8.24%
Operating Lease, Liability, Noncurrent 3K USD -99.1%
Liabilities 26.1M USD -18.1%
Retained Earnings (Accumulated Deficit) -289M USD -7.64%
Stockholders' Equity Attributable to Parent -20M USD -302%
Liabilities and Equity 6.04M USD -77.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.81M USD +28.2%
Net Cash Provided by (Used in) Financing Activities -7.5M USD -207%
Net Cash Provided by (Used in) Investing Activities 11K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 3.07M shares -96.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.3M USD -472%
Interest Paid, Excluding Capitalized Interest, Operating Activities 430K USD +44.8%
Deferred Tax Assets, Valuation Allowance 80M USD +11.7%
Deferred Tax Assets, Gross 80M USD +11.7%
Operating Lease, Liability 847K USD -42%
Depreciation 71K USD -40.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 876K USD -43.3%
Property, Plant and Equipment, Gross 331K USD -16.8%
Operating Lease, Liability, Current 315K USD -54.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 134K USD -81%
Lessee, Operating Lease, Liability, to be Paid, Year One 740K USD +3.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29K USD -65.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2K USD -98.4%
Deferred Tax Assets, Operating Loss Carryforwards 58.3M USD +1.07%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.4M USD -25.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%